H.C. Wainwright raised the firm’s price target on TG Therapeutics to $41 from $34 and keeps a Buy rating on the shares, citing an increased Briumvi revenue estimates and the impact of the upfront payment from the Neuraxpharm deal to its year-end cash estimate following the company’s Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics (NASDAQ:TGTX) Collapses 47% amid Disappointing Results
- TG Therapeutics, Neuraxpharm enter ex-U.S. commercialization agreement
- TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- TG Therapeutics expects cash to fund operations for ‘foreseeable future’
- TG Therapeutics reports Q2 EPS (34c), consensus (25c)